U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

U.S. Food and Drug Administration
  1. Home
  2. Drugs
  3. Drug Safety and Availability
  4. Information by Drug Class
  5. Past public meetings relevant to consumer and health care antiseptics
  1. Information by Drug Class

Past public meetings relevant to consumer and health care antiseptics

January 1997
NDAC Meeting
(Joint meeting with the Anti-Infective Drug Advisory Committee)
(January 6, 1997, 62 FR 764) (PDF - 20.28 MB)		Antiseptic and antibiotic resistance in relation to an industry proposal for consumer and health care antiseptic effectiveness testing (Health Care Continuum Model)
March 2005
NDAC Meeting
(February 18, 2005, 70 FR 8376)		The use of surrogate endpoints and study design issues for in vivo testing of health care antiseptics
October 2005
NDAC Meeting
(September 15, 2005, 70 FR 54560)		Benefits and risks of consumer antiseptics.  NDAC expressed concern about the pervasive use of consumer antiseptic washes where there are potential risks and no demonstrable benefit.  To demonstrate a clinical benefit, NDAC recommended clinical outcome studies to show that antiseptic washes are superior to non-antibacterial soap and water
November 2008
Public Feedback Meeting
(PDF - 3.01 MB)
(PDF - 137 KB)
(PDF - 866 KB)		Demonstration of the effectiveness of consumer antiseptics
September 2014
NDAC Meeting
(July 29, 2014, 79 FR 44042)		Safety testing framework for health care antiseptic active ingredients

 

Back to Top